Clinical trials: Cerebral Vascular Disorder
Cardiac Diseases, Muscular Weakness
Biomarker for Pompe Disease (BioPompe)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)
- Conditions
- Cardiac Diseases, Muscular Weakness, Hepato-splenomegaly, Lung Disease
- Trial name
- BioPompe (NCT01457443)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Intracerebral Hemorrhage, Cerebral Hemorrhage
ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)
This is a multicenter, randomized, adaptive clinical trial comparing standard medical management to early (<24 hours) surgical hematoma evacuation using minimally invasive parafascicular surgery (MIPS) in the treatment of acute…
- Conditions
- Intracerebral Hemorrhage, Cerebral Hemorrhage, Intracerebral Haemorrhage
- Trial name
- ENRICH (NCT02880878)
- Testing
- Early Surgical Hematoma Evacuation
- Where
- 36 sites in United States
- Volunteers
- 300 people
- Sponsor
- Nico Corporation
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947985
- Testing
- Rivaroxoban (Xarelto, Bay59-7939), Standard of care
- Where
- Netherlands
- Volunteers
- 208,958 people
- Sponsor
- Bayer
ST Elevation Myocardial Infarction
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST…
- Trial name
- NCT05601999
- Testing
- GNR-060, Metalyse
- Where
- 11 sites in Russia
- Volunteers
- 244 people
- Sponsor
- AO GENERIUM
Chronic Subdural Hematomas
PHIL™ Middle Meningeal Artery Embolization for First-Line Treatment of Chronic Subdural Hematoma IDE Trial
This is a prospective, randomized, controlled, open-label, blinded endpoint (PROBE) clinical investigation in which patients with non-emergent chronic subdural hematoma (cSDH) requiring treatment will be randomized (1:1) to…
- Trial name
- PHILFIRST (NCT07576998)
- Testing
- PHIL™ (Precipitating Hydrophobic Injectable Liquid), Surgical evacuation
- Volunteers
- 475 people
- Sponsor
- Microvention-Terumo, Inc.
Traumatic Brain Injury (TBI) Patients, Stroke Hemorrhagic
Non-invasive Intracranial Pressure Monitoring to Improve Emergency Care in Brazil's Public Health System
The goal of this observational study is to evaluate the diagnostic accuracy of non-invasive intracranial pressure (ICP) and intracranial compliance (ICC) pulse morphology and associated parameters (such as the P2/P1 ratio and…
- Conditions
- Traumatic Brain Injury (TBI) Patients, Stroke Hemorrhagic, Stroke Ischemic
- Trial name
- NCT07210333
- Testing
- non-invasive intracranial pressure monitoring
- Where
- 3 sites in Brazil
- Volunteers
- 300 people
- Sponsor
- Braincare USA Corp
Ischemic Stroke
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke.
- Trial name
- NCT01208233
- Testing
- PF-03049423
- Where
- 70 sites in United States, Bulgaria and 8 more
- Volunteers
- 181 people
- Sponsor
- Pfizer
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
Atrial Fibrillation (AF)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-ATLAS (NCT07175428)
- Testing
- REGN7508, REGN9933, Apixaban
- Where
- 91 sites in United States, Argentina and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Regeneron Pharmaceuticals
Cerebrovascular Accident
Rt-PA in the Treatment of Acute Ischemic Stroke
To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to…
- Trial name
- NCT00153036
- Where
- 142 sites in Austria, Belgium and 17 more
- Volunteers
- 821 people
- Sponsor
- Boehringer Ingelheim
Stroke
Portable EMG-triggered Hand Robot for Individuals After Stroke
This is an interventional pilot study investigating the feasibility of using the hand of hope (HOH) device for individuals with decreased hand function after stroke.
- Trial name
- NCT02364700
- Testing
- Hand of Hope (HOH)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rehab-Robotics Company Limited
Stroke
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
The purpose of this study is to evaluate the safety and tolerability of SUN13837 and to determine whether SUN13837 improves the physical performance, relative to placebo, following an acute stroke in adult subjects.
- Trial name
- NCT02258880
- Testing
- SUN13837
- Where
- 53 sites in United States, Canada and 2 more
- Sponsor
- Daiichi Sankyo
Cerebral Infarction
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects.
- Trial name
- NCT02562183
- Testing
- kallikrein
- Where
- 7 sites in China
- Volunteers
- 2,186 people
- Sponsor
- Techpool Bio-Pharma Co., Ltd.
Subarachnoid Hemorrhage
Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage
The hypothesis is that intravenous infusion of sodium nitrite is safe and effective for the reversal of cerebral vasospasm after subarachnoid hemorrhage in patients with a cerebral aneurysm.
- Trial name
- NCT02176837
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Hope Pharmaceuticals
Post-stroke Aphasia
Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia
This is a single site, open label study with a single arm designed to assess the feasibility of use of caloric vestibular stimulation (CVS) in patients with post-stroke aphasia.
- Trial name
- NCT02270866
- Testing
- TNM Device
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Scion NeuroStim
Ischemic Stroke, Neovascularization
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24…
- Trial name
- DISTALS (NCT05152524)
- Testing
- Tigertriever 13
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 149 people
- Sponsor
- Rapid Medical
Stroke
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients after Stroke and clinical outcomes?
- Trial name
- NCT01453829
- Testing
- Harvesting and Isolation of Stem Cells
- Where
- Mexico
- Sponsor
- Ageless Regenerative Institute
Acute Ischemic Stroke
A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）
The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.
- Trial name
- NCT05295173
- Testing
- Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator
- Where
- 78 sites in China
- Volunteers
- 1,412 people
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
Aneurysm Cerebral
Complex Aneurysm Registry - Real-World Evidence Data Collection Intracranial Aneurysm Treatment Devices
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of commercially available MicroVention devices used for the endovascular treatment of intracranial aneurysms (IA) at the direction of…
- Trial name
- CAR (NCT06215105)
- Testing
- Intracranial Aneurysm Devices
- Where
- 5 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Microvention-Terumo, Inc.
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
- Trial name
- NCT00651729
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 279 people
- Sponsor
- Allergan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.